Within-session variability as quality control for oscillometry in health and disease.

Autor:	Harkness LM; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; NHMRC Centre of Excellence in Severe Asthma, New Lambton Heights, NSW, Australia.; Dept of Respiratory Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia., Patel K; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia., Sanai F; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; NHMRC Centre of Excellence in Severe Asthma, New Lambton Heights, NSW, Australia.; Dept of Respiratory Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia., Rutting S; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; Dept of Respiratory Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia., Cottee AM; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; Dept of Thoracic Medicine, Concord Repatriation General Hospital, Concord, NSW, Australia., Farah CS; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; Dept of Thoracic Medicine, Concord Repatriation General Hospital, Concord, NSW, Australia., Schoeffel RE; Dept of Respiratory Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia., King GG; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.; NHMRC Centre of Excellence in Severe Asthma, New Lambton Heights, NSW, Australia.; Dept of Respiratory Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia., Thamrin C; Airway Physiology and Imaging Group, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia.
Jazyk:	angličtina
Zdroj:	ERJ open research [ERJ Open Res] 2021 Oct 11; Vol. 7 (4). Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).
DOI:	10.1183/23120541.00074-2021
Abstrakt:	Oscillometry is increasingly adopted in respiratory clinics, but many recommendations regarding measurement settings and quality control remain subjective. The aim of this study was to investigate the optimal number of measurements and acceptable within-session coefficient of variation (CoV) in health, asthma and COPD. 15 healthy, 15 asthma and 15 COPD adult participants were recruited. Eight consecutive 30-s measurements were made using an oscillometry device, from which resistance at 5 Hz ( R rs 5 ) was examined. The effect of progressively including a greater number of measurements on R rs 5 and its within-session CoV was investigated. Data were analysed using one-way repeated-measures ANOVA with Bonferroni post hoc test. The CoV( R rs 5 ) of the first three measurements was 6.7±4.7%, 9.7±5.7% and 12.6±11.2% in healthy, asthma and COPD participants, respectively. Both mean R rs 5 and CoV( R rs 5 ) were not statistically different when progressively including four to eight measurements. Selecting the three closest R rs 5 values over an increasing number of measurements progressively decreased the CoV( R rs 5 ). In order for ≥95% of participants to fall within a target CoV( R rs 5 ) of 10%, four or more, five and six measurements were needed in health, asthma and COPD, respectively. Within-session variability of oscillometry is increased in disease. Furthermore, the higher number of measurements required to achieve a set target for asthma and COPD patients may not be practical in a clinical setting. Provided technical acceptability of measurements is established, i.e. by removing artefacts and outliers, then a CoV of 10% is a marker of quality in most patients, but we suggest higher CoVs up to 15-20% should still be reportable. Competing Interests: Conflict of interest: L.M. Harkness is currently an employee of GSK but the work in this manuscript was conducted prior to that employment. Conflict of interest: K. Patel has nothing to disclose. Conflict of interest: F. Sanai has nothing to disclose. Conflict of interest: S. Rutting has nothing to disclose. Conflict of interest: A.M. Cottee has nothing to disclose. Conflict of interest: C.S. Farah has nothing to disclose. Conflict of interest: R.E. Schoeffel has nothing to disclose. Conflict of interest: G.G. King reports grants, personal fees and nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, MundiPharma and Novartis; unrestricted research grants from NHMRC, Boehringer Ingelheim, CycloPharma, GlaxoSmithKline, Menarini, MundiPharma, and philanthropic individuals and societies; and nonfinancial and other support from Restech, Italy during the conduct of the study. Conflict of interest: C. Thamrin has a patent WO 2006130922 A1 issued, which is broadly relevant to the work. In addition, C. Thamrin has intellectual property arrangements with THORASYS Medical Systems and Restech srl relating to research collaborations, but does not have any financial relationships with either company. (Copyright ©The authors 2021.)
Databáze:	MEDLINE
Externí odkaz: